Poseida Therapeutics gets FDA orphan drug designation for P-BCMA-ALLO1 in multiple myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a trailblazer in the field of clinical-stage cell and gene therapy, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to its cutting-edge treatment for multiple myeloma, P-BCMA-ALLO1. This novel therapy, a B-cell maturation antigen (BCMA)-targeted allogeneic T stem cell memory (TSCM)-rich […]